Post-Pregnancy Itching: Evaluation and Management

Introduction to Intrahepatic Cholestasis of Pregnancy

The American College of Obstetricians and Gynecologists notes that intrahepatic cholestasis of pregnancy (ICP) is the most important pathological cause of itching during pregnancy, characterized by intense pruritus, elevated serum bile acids, and elevated liver transaminases 1, 2, 3
ICP affects 0.3-2.0% of pregnancies in Europe and typically presents in the second or third trimester, with the European Association for the Study of the Liver recommending close monitoring 4
The condition spontaneously resolves within 4-6 weeks after delivery in the vast majority of cases, as stated by the Journal of Hepatology 4, 5
Pruritus impairs maternal quality of life but poses minimal risk to the mother; however, it carries potential fetal risks including prematurity and stillbirth, according to the American Journal of Obstetrics and Gynecology 4, 1

The American Association for the Study of Liver Diseases recommends that pruritus and elevated bile acids should completely resolve within 4-6 weeks postpartum, and liver function tests should normalize during this same timeframe 4, 6, 5
Pruritus persisting beyond 6 weeks postpartum suggests underlying chronic liver disease, such as primary biliary cholangitis, primary sclerosing cholangitis, ABCB4 deficiency, or chronic hepatitis C, as indicated by the Journal of Hepatology 4, 5, 7
Persistent abnormal liver tests after delivery warrant reconsideration of chronic hepatobiliary conditions, according to the European Association for the Study of the Liver 5

Genetic variants in hepatocanalicular transport proteins and bile acid sensors have been identified in some ICP patients, as reported by the Journal of Hepatology 4
Hormonal factors play a central role in ICP, evidenced by higher ICP incidence in twin pregnancies and triggering by high-dose oral contraceptives and progesterone, according to the American Journal of Obstetrics and Gynecology 4
The clinical evaluation algorithm for post-pregnancy itching includes measuring serum bile acids, ALT, AST, bilirubin, GGT, and prothrombin time, as recommended by the American Association for the Study of Liver Diseases 4, 5

Ursodeoxycholic acid (UDCA) is safe in pregnancy and lactation and should be continued postpartum for primary biliary cholangitis (PBC), as stated by the American Association for the Study of Liver Diseases 6
Multifaceted pruritus management includes cholestyramine, rifampin, S-adenosyl-L-methionine, and antihistamines, according to the European Association for the Study of the Liver 6
Monitor prothrombin time regularly due to vitamin K deficiency risk from cholestasis, particularly if using cholestyramine, as recommended by the American Journal of Obstetrics and Gynecology 6, 5

Never assume ICP has resolved if symptoms persist beyond 6 weeks postpartum, as this indicates underlying chronic liver disease requiring workup, according to the Journal of Hepatology 4, 5, 7
Do not miss vitamin K deficiency in patients with persistent cholestasis, especially those on cholestyramine, as this can lead to hemorrhage, as warned by the American Association for the Study of Liver Diseases 6, 5
Recognize that up to 90% recurrence risk exists in subsequent pregnancies for women who had ICP, as reported by the American Journal of Obstetrics and Gynecology 8
Family history is significant, as familial clustering suggests genetic susceptibility requiring counseling for future pregnancies, according to the European Association for the Study of the Liver 4, 8

The American Association for the Study of Liver Diseases recommends considering genetic testing in women with severe ICP (total bile acids >100 μmol), recurrent ICP, or early-onset ICP, as genetic mutations in hepatic phospholipid transporter (ABCB4), bile salt export pump (ABCB11), and ATP8B1 explain familial clustering and ethnic predisposition 9, 10
The American Association for the Study of Liver Diseases notes that maternal risk factors for ICP include advanced maternal age, multiparity, metabolic syndrome, and HCV infection, affecting 0.4%-10% of pregnancies depending on geography and ethnicity, with highest rates among Latina women (up to 5.6% in the United States) 9

The American College of Gastroenterology states that the classic symptom of ICP is generalized pruritus most severe in palms and soles without an accompanying rash, typically presenting in the second or third trimester (80% after 30 weeks gestation), with AST and ALT levels may be elevated 2-fold to 30-fold higher than normal 9, 10

The American Association for the Study of Liver Diseases reports that recurrent ICP is reported in 40%-92% of women with a personal history of ICP, with family history being significant as familial clustering suggests genetic susceptibility requiring counseling for future pregnancies 9

The American Association for the Study of Liver Diseases notes that women with genetic variants in ABCB11, ABCB4, or ATP8B1 have a different risk profile and may develop benign recurrent intrahepatic cholestasis, progressive familial intrahepatic cholestasis, or progressive liver disease, gallstones, cholangitis, and possibly liver cancer 9, 10